Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q1 FY2023 Earnings Presentation
18 slides from Strides Pharma Science's earnings presentation, Jul 29, 2022
Slide 1: Q1FY23 Earnings Update
Q1FY23 Earnings Update Strides Pharma Science Limited July 29, 2022
Slide 2: Strides reports an improved Q1FY23 with visible growth momentum
Strides reports an improved Q1FY23 with visible growth momentum Quarterly Performance (₹m) Particulars Q1 FY23 Q4 FY22 Q1 FY22 QoQ YoY We have started the new fiscal on a healthy note. Our strategy is now gaining traction across the front-end and partner-led businesses. Our customer engagement Reven
Slide 3: While the key businesses deliver steady performance, our cost control measures are yielding results
While the key businesses deliver steady performance, our cost control measures are yielding results ▸ US revenues at ₹3,552m ($46m) for Q1FY23, up from ₹3,301m ($44m) in Q4FY22 and ₹3,016m ($41m) in Q1FY22 ▸ US business contributed 38% of consolidated revenues in Q1FY23 US business continues ▸ Chest
Slide 4: Market Wise Outlook
Market Wise Outlook
Slide 5: US business continued the growth momentum during the quarter
US business continued the growth momentum during the quarter; Customer transition of Chestnut Ridge portfolio led to spill in revenues, transition now completed with visible ramp up in Q2FY23 US Revenues - Quarterly Trend ($m) Quarterly Updates Chestnut portfolio • Revenues from the US for Q1FY23 st
Slide 6: Other Regulated Markets revenues at $39m; order book visibility remains healthy
Other Regulated Markets (ORM) revenues at $39m in Q2FY23 Order book visibility remains healthy, business witnesses' currency headwinds during the quarter ORM Revenues - Quarterly Trend ($m) Business updates • Revenues from the ORM for Q1FY23 stood at ₹3,047 ($39m), up 37% YoY, • ORM business contrib
Slide 7: Emerging and Access markets continue to deliver strong performance with 71% YoY growth
Emerging and Access markets continue to deliver strong performance with 71% YoY growth EM Revenues - Quarterly Trend ($m) Business updates • Revenues from emerging markets for Q1FY23 stood at ₹2,858m ($37m), up 26% QoQ and 37 71% YoY. 29 29 30 28 • The institutional business reported revenues of ₹2,
Slide 8: Financial Performance
Financial Performance
Slide 9: Key P&L Highlights – Q1 FY23
Key P&L Highlights – Q1 FY23 Income statement (₹m) Particulars Q1 FY23 Q4 FY22 Q1 FY22 QoQ YoY Revenues 9,457 8,699 6,919 9% 37% EBITDA 657 461 -468 43% 100%+ EBITDA % 7% 5% -7% 170 bps 1,380 bps Reconciliation of EBITDA (₹m) As per SEBI results Q1 FY23 Q4 FY22 Q1 FY22 Profit before exceptional item
Slide 10: Details on Non-operational items in Q1FY23
Details on Non-operational items in Q1FY23 Exceptional items in P&L for Q1 FY23 (₹m) Particulars Description Q1FY23 Exchange Gain / (Loss) Relating to long term loans and deferred consideration -498 Product recall and inventory provision Past recall and other inventory provisions -53 Business combin
Slide 11: Reduction in gross debt through free cash flow generation a key focus area in FY23
Reduction in gross debt through free cash flow generation and corporate actions a key focus area in FY23 Q1FY23 Debt book Debt reduction initiatives planned for FY23 March’22 June’22 Realization of deferred from Arrow transaction to be used for repayment of debt Particulars Value in ₹ m Value in ₹ m
Slide 12: Update on Stelis Biopharma
Update on Stelis Biopharma
Slide 13: Promising beginning for Stelis as we received EUGMP certification for two facilities
Promising beginning for Stelis as we received EUGMP certification for two of our biopharmaceutical facilities A high capital long gestation investment now ready for significant growth and operational profitability • Stelis has emerged as a biopharmaceutical company with integrated capabilities in de
Slide 14: CDMO Division Updates (Operated as Stelis)
CDMO Division Updates (Operated as Stelis) • Significant progress was achieved during the first quarter as we onboarded six new Global partners for the business. The Drug Product facility continues to receive traction from the partners, with at least 10+ new products in the queue for different miles
Slide 15: Product Division Updates (Operated as Biolexis)
Product Division Updates (Operated as Biolexis) • STLP001 (PTH) is nearing European Medicine Agency(EMA) approval as Stelis completes the facility inspection (EUGMP), which was one of the prerequisites for Biosimilars acceptance. The approval is expected within 2022, and Stelis has already partnered
Slide 16: Earnings Call Details
Earnings Call Details
Slide 17: Strides Pharma Science Ltd – Q1FY23 Earnings Call
Strides Pharma Science Ltd – Q1FY23 Earnings Call invites you to interact with the senior management on Q1FY23 Pre-register and join without operator CLICK HERE Friday, 29th July 2022 4:00pm IST / 11:30am BST / 6:30am EDT / 6:30pm HKT Join through an operator using dial in numbers India Primary +91
Slide 18: Thank You
Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924/ 2789 3199 Fax: +91 22 2789 2942 Email: corpcomm@strides.com Website: www.strides.com CORPORATE OFFICE Strides House, Bilekahalli
Strides Pharma Science — Q1 FY2023 Earnings Presentation on 6ix